Trial Profile
A randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of MK-0677 [ibutamoren] 25 mg in the treatment of primary fibromyalgia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Ibutamoren (Primary)
- Indications Fibromyalgia
- Focus Therapeutic Use
- 03 Aug 2012 Additional lead trial investigator (Bennett R) added as reported by ClinicalTrials.gov record.
- 02 Sep 2010 Results were reproted at the 13th World Congress on Pain.
- 02 Sep 2010 Primary endpoint 'Fibromyalgia Impact Questionnaire' has not been met.